Mesentech is a pre-clinical platform company developing drug-conjugates targeted to bone. Our first product is a regenerative medicine product that targets mesenchymal stem-cells with a potent (sub nano-molar) prostaglandin mimetic that is released selectively in bone resulting in bone-regeneration. This drug can be used systemically to treat low-bone-density disorders or for local indications such as fracture-healing.